metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)
versus sunitinib
	atezolizumab alone
	IMmotion-150 (At - all population), 2018 Nat. Med. 2018; 24:749-757 BJU Int 2020 Jul;126(1):73-82. NCT01984242	RCT	metastatic/advanced RCC (mRCC) - 1st line (L1)	atezolizumab	sunitinib	unresectable advanced or mRCC with a component of clear cell histology and/or sarcomatoid histology not previously treated with any systemic agents for RCC	103 / 101	some concern	inconclusive	inconclusive 19 % increase in progression or deaths (PFS) (PE)
mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive
versus sunitinib
	atezolizumab alone
	IMmotion-150 (At - PDL1>1%), 2018 Nat. Med. 2018; 24:749-757 BJU Int 2020 Jul;126(1):73-82. NCT01984242	RCT	mRCC - L1 - PDL1 positive	atezolizumab	sunitinib	unresectable advanced or mRCC with a component of clear cell histology and/or sarcomatoid histology not previously treated with any systemic agents for RCC. Patients had PDL1 >1%	54 / 60	some concern	inconclusive	inconclusive 3 % increase in progression or deaths (PFS) (PE)